1 While patients may receive targeted multi-gene panel testing, there are more than ... compared to a previously reported 19% diagnostic yield for epilepsy gene panels. 3 The Patient Access ...

Capsida Biotherapeutics has unveiled data showing that its AAV-delivered gene therapy for developmental and epileptic encephalopathy (DEE), the most severe form of epilepsy, corrected cognitive ...

"Since the therapy has shown promise in targeting a specific gene mutation causing epilepsy, we hope to eventually pioneer ...

"While epilepsy is a fairly common condition, affecting nearly a half a million children under age 18 in the US, its genetic origins are still insufficiently understood. Through increased access ...